Filana Therapeutics Publishes Preclinical Data on Epilepsy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 15 2026
0mins
Should l Buy FLNA?
Filana Therapeutics announced publication in Epilepsia of preclinical data showing that simufilam attenuated seizure progression in a well-accepted mouse model of severe TSC-related epilepsy. The results support the continued evaluation of simufilam for the treatment of TSC-related epilepsy. Simufilam is an oral small molecule intended to modulate filamin A protein. Top line results of the study were previously reported by the company in August 2025. The work was conducted in collaboration with the TSC Alliance and PsychoGenics, Inc., the clinical research partner of the TSC Preclinical Consortium. This dose escalation study evaluated simufilam's ability to slow the worsening of seizures in the Tsc1 conditional knockout mouse, an exceptionally severe and progressive model of TSC-related epilepsy. Seizures were monitored for approximately three weeks following onset. The data showed that simufilam attenuated the progression of seizure activity compared to vehicle, with a statistically significant correlation between simufilam dose and the number of seizures by the end of the study. The study evaluated simufilam in the Tsc1-cKO mouse, an exceptionally severe and rapidly progressive model of TSC-related epilepsy. In this model, seizures normally worsen steadily over time. Simufilam attenuated the expected worsening of seizures over time in both number and total duration. Attenuation of seizure worsening increased with drug exposure. Mice were administered vehicle or simufilam at one of three ascending doses. Filana Therapeutics is working to address the previously disclosed request for information from FDA that was contained in a December 2025 Clinical Hold Letter, including the submission of additional pre-clinical data and protocol design modifications. The company intends to submit a response to FDA following completion of these activities and expects to provide a program update in the coming months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FLNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FLNA
Wall Street analysts forecast FLNA stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 1.240
Low
Averages
High
Current: 1.240
Low
Averages
High
No data
About FLNA
Filana Therapeutics, Inc., formerly Cassava Sciences, Inc., is a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, is an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cassava Sciences Q1 Earnings Beat Expectations
- Earnings Beat: Cassava Sciences reported a Q1 GAAP EPS of -$0.21, exceeding expectations by $0.02, indicating a slight improvement in financial performance despite still being in a loss position.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $86.6 million, down from $95.5 million as of December 31, 2025, reflecting the cash burn in its operations.
- Debt-Free Status: The company currently holds no debt, providing financial flexibility for future operations and potentially attracting investor interest in its ongoing developments.
- Future Cash Estimates: The company estimates cash reserves to be between $47 million and $50 million by June 30, 2026, which will influence its future operational strategies and funding arrangements.
See More
Filana Therapeutics Presents Clinical Development Program for Simufilam
- Scientific Presentation: Filana Therapeutics outlined the biological rationale for its clinical development program for Simufilam at the 18th Eilat conference on new antiepileptic drugs, but this announcement led to shares dropping to a 52-week low of $1.38, indicating investor skepticism.
- Disease Context: Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in the TSC1 and TSC2 genes, affecting the mTOR pathway and leading to tumor formation, with 80%-90% of patients experiencing seizures, and over 60% remaining refractory to existing treatments, highlighting the urgent need for new therapies.
- Drug Development: Simufilam is an investigational drug designed to modulate the filamin A protein, whose dysregulation is linked to various central nervous system disorders, including TSC, and the company's progress in this area could significantly impact future market dynamics.
- FDA Oversight: The company is actively addressing a request for information from the FDA regarding a Clinical Hold Letter issued in December 2025, intending to submit additional preclinical data and protocol modifications to facilitate a response, with program updates expected in the coming months that may influence investor confidence.
See More
Cassava Sciences Reports Q4 2025 Financial Results
- Financial Overview: Cassava Sciences reported a Q4 GAAP EPS of -$0.26 for fiscal year 2025, indicating ongoing challenges in profitability that may negatively impact investor confidence.
- Cash Flow Status: The company utilized $32.3 million in cash for operations in 2025, consistent with prior guidance, ending the year with $95.5 million in cash, while projecting a decrease to between $47 million and $50 million by June 30, 2026, reflecting liquidity pressures.
- Future Cash Usage Estimates: The estimated cash use for operations in the first half of 2026 is projected to be between $14 million and $17 million, in addition to a $31.25 million payment for potential litigation settlement, which could further affect the company's financial stability.
- Rebranding Initiative: Cassava Sciences plans to rebrand as Filana Therapeutics, indicating a strategic shift in brand image and market positioning aimed at enhancing market recognition and attracting more investor interest.
See More
Cassava Sciences Q1 Earnings Beat Expectations
- Earnings Beat: Cassava Sciences reported a Q1 GAAP EPS of -$0.21, exceeding expectations by $0.02, indicating a slight improvement in financial performance despite still being in a loss position.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $86.6 million, down from $95.5 million as of December 31, 2025, reflecting the cash burn in its operations.
- Debt-Free Status: The company currently holds no debt, providing financial flexibility for future operations and potentially attracting investor interest in its ongoing developments.
- Future Cash Estimates: The company estimates cash reserves to be between $47 million and $50 million by June 30, 2026, which will influence its future operational strategies and funding arrangements.
See More
Filana Therapeutics Presents Clinical Development Program for Simufilam
- Scientific Presentation: Filana Therapeutics outlined the biological rationale for its clinical development program for Simufilam at the 18th Eilat conference on new antiepileptic drugs, but this announcement led to shares dropping to a 52-week low of $1.38, indicating investor skepticism.
- Disease Context: Tuberous sclerosis complex (TSC) is a rare genetic disorder caused by mutations in the TSC1 and TSC2 genes, affecting the mTOR pathway and leading to tumor formation, with 80%-90% of patients experiencing seizures, and over 60% remaining refractory to existing treatments, highlighting the urgent need for new therapies.
- Drug Development: Simufilam is an investigational drug designed to modulate the filamin A protein, whose dysregulation is linked to various central nervous system disorders, including TSC, and the company's progress in this area could significantly impact future market dynamics.
- FDA Oversight: The company is actively addressing a request for information from the FDA regarding a Clinical Hold Letter issued in December 2025, intending to submit additional preclinical data and protocol modifications to facilitate a response, with program updates expected in the coming months that may influence investor confidence.
See More
Cassava Sciences Reports Q4 2025 Financial Results
- Financial Overview: Cassava Sciences reported a Q4 GAAP EPS of -$0.26 for fiscal year 2025, indicating ongoing challenges in profitability that may negatively impact investor confidence.
- Cash Flow Status: The company utilized $32.3 million in cash for operations in 2025, consistent with prior guidance, ending the year with $95.5 million in cash, while projecting a decrease to between $47 million and $50 million by June 30, 2026, reflecting liquidity pressures.
- Future Cash Usage Estimates: The estimated cash use for operations in the first half of 2026 is projected to be between $14 million and $17 million, in addition to a $31.25 million payment for potential litigation settlement, which could further affect the company's financial stability.
- Rebranding Initiative: Cassava Sciences plans to rebrand as Filana Therapeutics, indicating a strategic shift in brand image and market positioning aimed at enhancing market recognition and attracting more investor interest.
See More
